WO2001035811A3 - Methods of diagnosing and determining prognosis of breast cancer - Google Patents

Methods of diagnosing and determining prognosis of breast cancer Download PDF

Info

Publication number
WO2001035811A3
WO2001035811A3 PCT/US2000/031736 US0031736W WO0135811A3 WO 2001035811 A3 WO2001035811 A3 WO 2001035811A3 US 0031736 W US0031736 W US 0031736W WO 0135811 A3 WO0135811 A3 WO 0135811A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
breast cancer
diagnosing
determining prognosis
prognosis
Prior art date
Application number
PCT/US2000/031736
Other languages
French (fr)
Other versions
WO2001035811A9 (en
WO2001035811A2 (en
Inventor
David Mack
Kurt C Gish
Original Assignee
Eos Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eos Biotechnology Inc filed Critical Eos Biotechnology Inc
Priority to AU17772/01A priority Critical patent/AU1777201A/en
Publication of WO2001035811A2 publication Critical patent/WO2001035811A2/en
Publication of WO2001035811A9 publication Critical patent/WO2001035811A9/en
Publication of WO2001035811A3 publication Critical patent/WO2001035811A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Described herein are methods that can be used for diagnosis and prognosis of breast cancer. Also described herein are methods that can be used to screen candidate bioactive agents for the ability to modulate breast cancer. Additionally, methods and molecular targets (genes and their products) for therapeutic intervention in breast and other cancers are described.
PCT/US2000/031736 1999-11-16 2000-11-16 Methods of diagnosing and determining prognosis of breast cancer WO2001035811A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU17772/01A AU1777201A (en) 1999-11-16 2000-11-16 Novel methods of diagnosing and determining prognosis of breast cancer, compositions, and methods of screening for breast cancer modulators

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44067699A 1999-11-16 1999-11-16
US09/440,676 1999-11-16

Publications (3)

Publication Number Publication Date
WO2001035811A2 WO2001035811A2 (en) 2001-05-25
WO2001035811A9 WO2001035811A9 (en) 2002-07-04
WO2001035811A3 true WO2001035811A3 (en) 2002-09-12

Family

ID=23749724

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/031736 WO2001035811A2 (en) 1999-11-16 2000-11-16 Methods of diagnosing and determining prognosis of breast cancer

Country Status (2)

Country Link
AU (1) AU1777201A (en)
WO (1) WO2001035811A2 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018945A1 (en) * 1996-10-31 1998-05-07 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
WO1999023230A1 (en) * 1997-10-31 1999-05-14 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
WO2000055629A2 (en) * 1999-03-15 2000-09-21 Eos Biotechnology, Inc. Methods of diagnosing and treating breast cancer
WO2000061756A2 (en) * 1999-04-09 2000-10-19 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO2001065262A2 (en) * 2000-02-29 2001-09-07 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
WO2001075171A2 (en) * 2000-04-03 2001-10-11 Corixa Corporation Methods, compositions and kits for the detection and monitoring of breast cancer
WO2001098339A2 (en) * 2000-06-22 2001-12-27 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018945A1 (en) * 1996-10-31 1998-05-07 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
WO1999023230A1 (en) * 1997-10-31 1999-05-14 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
WO2000055629A2 (en) * 1999-03-15 2000-09-21 Eos Biotechnology, Inc. Methods of diagnosing and treating breast cancer
WO2000061756A2 (en) * 1999-04-09 2000-10-19 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO2001065262A2 (en) * 2000-02-29 2001-09-07 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
WO2001075171A2 (en) * 2000-04-03 2001-10-11 Corixa Corporation Methods, compositions and kits for the detection and monitoring of breast cancer
WO2001098339A2 (en) * 2000-06-22 2001-12-27 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer

Also Published As

Publication number Publication date
WO2001035811A9 (en) 2002-07-04
WO2001035811A2 (en) 2001-05-25
AU1777201A (en) 2001-05-30

Similar Documents

Publication Publication Date Title
WO2000055629A3 (en) Methods of diagnosing and treating breast cancer
WO2001031335A3 (en) Cell proliferation diagnosis and screening for modulators
WO2000055633A3 (en) Methods of screening for colorectal cancer modulators
WO2002021996A3 (en) Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators
WO2002055988A3 (en) Novel methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
CA2164498A1 (en) Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices
TR200200937T2 (en) Compositions for the treatment of ovarian cancer.
WO2001011086A3 (en) Methods of screening for angiogenesis modulators
EE200100507A (en) Hydroxymatairesinol for cancer prevention
AU2002246668A1 (en) Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc)
WO2004046332A3 (en) Amplified genes involved in cancer
WO2003079982A3 (en) Gene amplification in cancer
EP1064005A4 (en) Urokinase plasminogen activator receptor as a target for diagnosis of metastases
WO2001002556A3 (en) Agents for the diagnosis, prognosis and treatment of malignant diseases
WO2002016939A3 (en) Methods of diagnosis of cancer and screening for cancer modulators
MXPA02011563A (en) Compositions and methods for the therapy and diagnosis of breast cancer.
WO2001035811A3 (en) Methods of diagnosing and determining prognosis of breast cancer
WO2002059609A3 (en) Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators
WO2002021134A3 (en) Methods of diagnosing breast cancer and screening for modulators
WO2004084804A3 (en) Detection and monitoring of lung cancer
WO2001004343A3 (en) A method for determining the prognosis of cancer patients by measuring levels of bag expression
YU63702A (en) Novel antibody with specificity for colon cancer
WO2000042972A3 (en) Compositions and methods for intraductal gene therapy
DE60130541D1 (en) TISSUE-SPECIFIC PROTEIN 103P2D6, HIGHLY EXPRESSED IN DIFFERENT CANCER TYPES
WO2002064838A3 (en) Amplified cancer gene wip1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/6-6/6, DRAWINGS, REPLACED BY NEW PAGES 1/3-3/3; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)